Abiopharma

🔍 Wassil Jim (Executive)

Company: Vaxcyte, Inc. (PCVX)

Report Date: 2026-03-09

Detailed Transactions and Holdings:

• Sold 975 shares of Common Stock at $59.32 per share (Direct)
  Date: 2026-03-09 | Code: F | equity_swap_involved: 0 | shares_owned_after: 174,213.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 2,427 shares of Common Stock at $58.316 per share (Direct)
  Date: 2026-03-10 | Code: S | equity_swap_involved: 0 | shares_owned_after: 171,786.00 | transaction_form_type: 4 | Footnotes: F2, F3
• Sold 4,968 shares of Common Stock at $59.16 per share (Direct)
  Date: 2026-03-10 | Code: S | equity_swap_involved: 0 | shares_owned_after: 166,818.00 | transaction_form_type: 4 | Footnotes: F2, F4

Footnotes:

• F1: Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of RSUs. No other shares of common stock subject to the restrictions on transfer set forth in a Lock-Up Agreement dated January 29, 2026 were sold by the Reporting Person.
• F2: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on December 9, 2025.
• F3: The price reported is a weighted-average price. The shares were sold at prices ranging from $57.725 to $58.715. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
• F4: The price reported is a weighted-average price. The shares were sold at prices ranging from $58.74 to $59.575. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.